Protalix BioTherapeutics
PLX
$1.14
Share price
-3.39%
Change (1 day)
-53.47%
Change (1 year)
Categories
P/S ratio for Protalix BioTherapeutics (PLX)
P/S ratio as of April 2024 (TTM): 1.27
According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.27156. At the end of 2023 the company had a P/S ratio of 1.98.
P/S ratio history for Protalix BioTherapeutics from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 1.98 | 36.07% |
| 2022 | 1.46 | 47.48% |
| 2021 | 0.9880 | -48.65% |
| 2020 | 1.92 | 116.21% |
| 2019 | 0.8899 | -1.84% |
| 2018 | 0.9065 | -81.12% |
| 2017 | 4.80 | -19.81% |
| 2016 | 5.99 | |
| 2015 | N/A | -100% |
| 2014 | 11.4 | -64.03% |
| 2013 | 31.6 | 124.11% |
| 2012 | 14.1 | -66.53% |
| 2011 | 42.1 | -66.86% |
| 2010 | 127 | -90.79% |
| 2009 | > 1000 | -100% |
| 2008 | > 1000 | |
| 2001 | > 1000 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.51 | 97.25% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 7.02 | 452.20% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | 7.88 | 520.08% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9810 | -22.85% | 🇮🇱 Israel |